Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00042068

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00042068. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 8:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

Study identification

NCT ID
NCT00042068
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
1,000 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2002 (Type not available)
Primary completion
Not listed
Completion
Jul 2003 (Type not available)
Last update posted
Nov 1, 2013

2002 – 2003

United States locations

U.S. sites
72
U.S. states
29
U.S. cities
65
Facility City State ZIP Site status
Suites 570 (research) & 600 (PI) Huntsville Alabama 35801 —
Suite 200 Montgomery Alabama 36106 —
Suite 140 Anchorage Alaska 99508 —
#106 Glendale Arizona 85308 —
Suite 601 Phoenix Arizona 85012 —
Suite 201 Phoenix Arizona 85015 —
Boehringer Ingelheim Investigational Site Los Angeles California 90048 —
Boehringer Ingelheim Investigational Site Pasadena California 91105 —
Suite 100 Rancho Cucamonga California 91730 —
Boehringer Ingelheim Investigational Site Rancho Mirage California 92270-4469 —
Suite 208 San Diego California 92108 —
Suite 202 San Diego California 92120 —
Suite 301 San Leandro California 94578 —
Suite A Santa Maria California 93454 —
Westlake Medical Research Westlake Village California 91361 —
Suite 200 Colorado Springs Colorado 80910 —
Suites 205 & 206 Danbury Connecticut 06810 —
Suite 300 Washington D.C. District of Columbia 20006 —
Boehringer Ingelheim Investigational Site Delray Beach Florida 33484 —
Boehringer Ingelheim Investigational Site Gainsville Florida 32607 —
Boehringer Ingelheim Investigational Site Jacksonville Florida 32204 —
Boehringer Ingelheim Investigational Site Largo Florida 33773 —
Suite 202 Miami Florida 33173 —
Boehringer Ingelheim Investigational Site Ocala Florida 03474 —
Renstar Medical Research Ocala Florida 34471 —
Boehringer Ingelheim Investigational Site Orlando Florida 32804 —
Suite 2 Orlando Florida 32806 —
Suite 406 Safety Harbor Florida 34695 —
Boehringer Ingelheim Investigational Site Sarasota Florida 34239 —
Boehringer Ingelheim Investigational Site South Miami Florida 33143 —
Suite 101 St. Petersburg Florida 33710 —
Radiant Research Stuart Florida 34996 —
Suite 203 Tampa Florida 33614 —
Boehringer Ingelheim Investigational Site Zephyrhills Florida 33540 —
Boehringer Ingelheim Investigational Site Coeur d'Alene Idaho 83814-2644 —
Suite 202 Idaho Falls Idaho 83404 —
Boehringer Ingelheim Investigational Site Lake Forest Illinois 60045 —
Boehringer Ingelheim Investigational Site Rockford Illinois 61103 —
Boehringer Ingelheim Investigational Site Springfield Illinois 62704 —
Boehringer Ingelheim Investigational Site Indianapolis Indiana 46202 —
Attn: Kathy Stoddard, Director Wichita Kansas 67207 —
Suite 306 Wheaton Maryland 20902 —
Truesdale Clinic Fall River Massachusetts 02720 —
Suite 202 Kalamazoo Michigan 49009 —
Suite 101 St Louis Missouri 63128 —
Suite 240 St Louis Missouri 63141 —
Boehringer Ingelheim Investigational Site Lincoln Nebraska 68506 —
Boehringer Ingelheim Investigational Site Reno Nevada 89502-1196 —
PC, Jackson Commons D-2 Medford New Jersey 08055 —
Suite 8 Mercerville New Jersey 08619 —
Boehringer Ingelheim Investigational Site New York New York 10021 —
Suite 100 Charlotte North Carolina 28210 —
Boehringer Ingelheim Investigational Site Columbus Ohio 43214 —
Boehringer Ingelheim Investigational Site Tulsa Oklahoma 74135 —
Boehringer Ingelheim Investigational Site Camp Hill Pennsylvania 17011 —
Altoona Center for Clinical Research Duncansville Pennsylvania 16635 —
Boehringer Ingelheim Investigational Site Erie Pennsylvania 16508-1256 —
Suite D Mechanicsburg Pennsylvania 17055 —
Suite 331-333 Johnston Rhode Island 02919 —
Boehringer Ingelheim Investigational Site Columbia South Carolina 29204 —
Suite H North Charleston South Carolina 29406 —
Boehringer Ingelheim Investigational Site Orangeburg South Carolina 29118 —
Boehringer Ingelheim Investigational Site Austin Texas 78705 —
Boehringer Ingelheim Investigational Site Dallas Texas 75225 —
Radiant Research Dallas Texas 75231 —
Suite 200 Dallas Texas 75246-1632 —
Suite 500 Lubbock Texas 79410 —
Suites 207 San Antonio Texas 78217 —
Suite 2A Falls Church Virginia 22044 —
Boehringer Ingelheim Investigational Site Everett Washington 98201 —
Suite D-3 Seattle Washington 98166-2967 —
Boehringer Ingelheim Investigational Site Yakima Washington 98902 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00042068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2013 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.